Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
Shun Lü(Shanghai Jiao Tong University), Shucai Zhang(Northeastern University), Liangan Chen(Wenzhou Medical University), Chengshui Chen(Wenzhou Medical University), Guoping Sun(Anhui Medical University), Jiuwei Cui(Jilin University), Shundong Cang(Henan University), Jianying Zhou(First Affiliated Hospital Zhejiang University), Xiangming Jin(Ningxia Medical University), Zhe Liu(Capital Medical University), Dianming Li(Harbin Electric Corporation (China)), Liyan Jiang(Southwest University), Ying Cheng(Jilin Province Tumor Hospital), Renhua Guo(Sun Yat-sen University), Dongqing Lv(Wenzhou Medical University), Aimin Zang, Yiping Zhang(Zhejiang Cancer Hospital), Yan Yang(Southern Illinois University School of Medicine), Junquan Yang(Tangshan People's Hospital), Panwen Tian(Sichuan University), Rong Wu(China Medical University), Jian Fang(Peking University), Qun Chen(Stanford University), Xiaoling Li(University of Science and Technology of China), Guojun Zhang(Kunming Medical University), Qingshan Li(Chinese PLA General Hospital), Jian Zhang(Zhujiang Hospital), Kai Wang(Michigan United), Jun Chen(Fourth People's Hospital of Taiyuan), Yong Song(Nanjing General Hospital of Nanjing Military Command), Yan Zhang(Xijing Hospital), Zhuang Yu(Shanghai East Hospital), Donglin Wang(Shandong University), Bin Wang(Shandong University of Traditional Chinese Medicine), Xiuyi Zhi(Roswell Park Comprehensive Cancer Center), Hui Zhao(Dalian Medical University), Yunchao Huang(North China University of Water Resources and Electric Power), Qitao Yu(Guangxi Medical University), Min Zhao(Hospital of Hebei Province), Guanming Jiang(Dongguan People’s Hospital), Hong Jian(Shanghai Jiao Tong University), Wu Zhuang(Hunan University), Cuimin Ding(Hebei Medical University), Yunpeng Liu(Shenyang Institute of Automation), Lejie Cao(University of Science and Technology of China), Tienan Yi(Xiangyang Central Hospital), Gongyan Chen(Harbin Medical University), Yueyin Pan(University of Science and Technology of China), Gang Wu(Shanghai Jiao Tong University), Peiguo Cao(Central South University)
Cited by 25
Related Papers
Food, nutrition, physical activity, and the prevention of cancer: a global perspective
|Choice Reviews Online|2008|5.4k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k